PGR and breast carcinoma: Currently, the treatment of breast cancer is largely guided by ER, PR and HER2 status: ER+/PR + patients require effective endocrine therapy; HER2 + patients require anti-HER2 targeted therapy; however, due to the lack of effective therapeutic targets for TNBC, there is no specific targeted therapy available.